To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
White Paper from Premier Research Reviews how to Optimize Country Selection in Oncology Clinical Trials
Read time: Less than a minute
Premier Research Group Limited, an international CRO with significant oncology research experience and expertise, released a new white paper, available at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, that reviews a funnel-approach to selecting target countries for oncology trials.
A challenging reality in the field of oncology clinical research exists in that only a very small percentage of adult cancer patients participate in clinical research studies. This reality slows the progression and approval of new therapies for the treatment of cancer. Over the last decade an extensive amount of research has been directed at identifying the reasons for low enrollment of adult cancer patients into clinical trials.
This new white paper reviews a country selection strategy, not directed at systemically improving upon the low percentage of oncology trial participation, but rather it acknowledges this paradigm and positions cancer trials for success despite this reality.
Copies of the white paper will be available at the 2010 ASCO Annual Meeting, booth 22076 or can be downloaded from the Premier Research website.
A challenging reality in the field of oncology clinical research exists in that only a very small percentage of adult cancer patients participate in clinical research studies. This reality slows the progression and approval of new therapies for the treatment of cancer. Over the last decade an extensive amount of research has been directed at identifying the reasons for low enrollment of adult cancer patients into clinical trials.
This new white paper reviews a country selection strategy, not directed at systemically improving upon the low percentage of oncology trial participation, but rather it acknowledges this paradigm and positions cancer trials for success despite this reality.
Copies of the white paper will be available at the 2010 ASCO Annual Meeting, booth 22076 or can be downloaded from the Premier Research website.
